199 related articles for article (PubMed ID: 19478385)
1. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.
Mesker WE; Liefers GJ; Junggeburt JM; van Pelt GW; Alberici P; Kuppen PJ; Miranda NF; van Leeuwen KA; Morreau H; Szuhai K; Tollenaar RA; Tanke HJ
Cell Oncol; 2009; 31(3):169-78. PubMed ID: 19478385
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
3. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.
Polack M; Smit MA; van Pelt GW; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Putter H; Gelderblom H; Crobach ASLP; Terpstra V; Petrushevska G; Gašljević G; Kjær-Frifeldt S; de Cuba EMV; Bulkmans NWJ; Vink GR; Al Dieri R; Tollenaar RAEM; van Krieken JHJM; Mesker WE;
ESMO Open; 2024 Apr; 9(4):102988. PubMed ID: 38613913
[TBL] [Abstract][Full Text] [Related]
4. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial.
Zunder S; van der Wilk P; Gelderblom H; Dekker T; Mancao C; Kiialainen A; Putter H; Tollenaar R; Mesker W
Cell Oncol (Dordr); 2019 Oct; 42(5):717-725. PubMed ID: 31102145
[TBL] [Abstract][Full Text] [Related]
5. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
Zunder SM; van Pelt GW; Gelderblom HJ; Mancao C; Putter H; Tollenaar RA; Mesker WE
Br J Cancer; 2018 Jul; 119(2):164-169. PubMed ID: 29755119
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
7. Lumican and versican are associated with good outcome in stage II and III colon cancer.
de Wit M; Belt EJ; Delis-van Diemen PM; Carvalho B; Coupé VM; Stockmann HB; Bril H; Beliën JA; Fijneman RJ; Meijer GA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S348-59. PubMed ID: 22711178
[TBL] [Abstract][Full Text] [Related]
8. Expression of VEGF-D, SMAD4, and SMAD7 and Their Relationship with Lymphangiogenesis and Prognosis in Colon Cancer.
Su F; Li X; You K; Chen M; Xiao J; Zhang Y; Ma J; Liu B
J Gastrointest Surg; 2016 Dec; 20(12):2074-2082. PubMed ID: 27730400
[TBL] [Abstract][Full Text] [Related]
9. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
Huijbers A; Tollenaar RA; v Pelt GW; Zeestraten EC; Dutton S; McConkey CC; Domingo E; Smit VT; Midgley R; Warren BF; Johnstone EC; Kerr DJ; Mesker WE
Ann Oncol; 2013 Jan; 24(1):179-85. PubMed ID: 22865778
[TBL] [Abstract][Full Text] [Related]
10.
Sheng S; Xie L; Wu Y; Ding M; Zhang T; Wang X
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30745456
[TBL] [Abstract][Full Text] [Related]
11. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
12. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
15. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
[TBL] [Abstract][Full Text] [Related]
16. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients.
de Kruijf EM; van Nes JG; van de Velde CJ; Putter H; Smit VT; Liefers GJ; Kuppen PJ; Tollenaar RA; Mesker WE
Breast Cancer Res Treat; 2011 Feb; 125(3):687-96. PubMed ID: 20361254
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of tumour-stroma ratio in triple-negative breast cancer.
Moorman AM; Vink R; Heijmans HJ; van der Palen J; Kouwenhoven EA
Eur J Surg Oncol; 2012 Apr; 38(4):307-13. PubMed ID: 22264965
[TBL] [Abstract][Full Text] [Related]
18. Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.
Yan P; Klingbiel D; Saridaki Z; Ceppa P; Curto M; McKee TA; Roth A; Tejpar S; Delorenzi M; Bosman FT; Fiocca R
Clin Cancer Res; 2016 Jun; 22(12):3037-47. PubMed ID: 26861460
[TBL] [Abstract][Full Text] [Related]
19. Smad4 restoration leads to a suppression of Wnt/beta-catenin signaling activity and migration capacity in human colon carcinoma cells.
Tian X; Du H; Fu X; Li K; Li A; Zhang Y
Biochem Biophys Res Commun; 2009 Mar; 380(3):478-83. PubMed ID: 19284991
[TBL] [Abstract][Full Text] [Related]
20. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
